In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 5, 2003, Pages 385-394

  Vassal, Gilles ^a   Merlin, Jean Louis ^b   Terrier Lacombe, Marie José ^a   Grill, Jacques ^a   Parker, Fabrice ^c   Sainte Rose, Christian ^d   Aubert, Geneviève ^a   Morizet, Jackie ^a   Sévenet, Nicolas ^e   Poullain, Marie Gwenaëlle ^f   Lucas, Catherine ^f   Kalifa, Chantal ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c BICÊTRE HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSTITUT CURIE   (France)

^f INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Doxorubicin; Glioblastoma; Medulloblastoma; MRP1; Nitrosourea

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FOTEMUSTINE; N (2 DIMETHYLAMINOETHYL) 9 HYDROXY 5,6 DIMETHYL 6H PYRIDO[4,3 B]CARBAZOLE 1 CARBOXAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MEDULLOBLASTOMA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 0038018597     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0584-1     Document Type: Article

References (35)

1. Abe T, Hasegawa S, Taniguchi K, Yokomizo A, Kuwano T, Ono M, Mori T, Hori S, Kohno K, Kuwano M (1994) Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int J Cancer 58:860-864
2. Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SP, Koike K, Kuwano M, Hori S (1998) Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 40:11-18
3. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG (2000) The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 26:449-462
4. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD (1994) Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54:5036-5040
5. Chou PM, Reyes-Mugica M, Barquin N, Yasuda T, Tan X, Tomita T (1995) Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients. Pediatr Neurosurg 23:283-291
6. Cogen PH, McDonald JD (1996) Tumor suppressor genes and medulloblastoma. J Neurooncol 29:103-112
7. Cowan KH, Batist G, Tulpule A, Sinha BK, Myers CE (1986) Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci U S A 83:9328-9332
8. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 92:3963-3967
9. Grill J, Renaux VK, Bulteau C, Viguier D, Levy-Piebois C, Sainte-Rose C, Dellatolas G, Raquin MA, Jambaque I, Kalifa C (1999) Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 45:137-145
10. Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierre A, Atassi G (1996) In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer Chemother Pharmacol 38:513-521
11. Gussow D, Rein R, Ginjaar I, Hochstenbach F, Seemann G, Kottman A, Ploegh HL (1987) The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 139:3132-3138
12. Haas-Kogan DA, Kogan SS, Yount G, Hsu J, Haas M, Deen DF, Israel MA (1999) p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys 43:399-403
13. Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertrand P, Bizzari JP (1994) Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest 12:414-420
14. Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, Karkavitsas N (2000) High intratumoural accumulation of Stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 83:1281-1286
15. Kraus-Berthier L, Guilbaud N, Jan M, Saint-Dizier D, Rouillon MH, Burbridge MF, Pierre A, Atassi G (1997) Experimental antitumour activity of S 16020-2 in a panel of human tumours. Eur J Cancer 33:1881-1887
16. Le Mée S, Pierre A, Markovits J, Atassi G, Jacquemin-Sablon A, Saucier JM (1998) S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol Pharmacol 53:213-220
17. Leonce S, Perez V, Casabianca-Pignede MR, Anstett M, Bisagni E, Pierre A, Atassi G (1996) In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest New Drugs 14:169-180
18. Merlin JL, Bour-Dill C, Marchal S, Ramacci C, Poullain MG, Giroux B (2000) Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles. Cytometry 41:62-72
19. Mousseau M, Chauvin C, Nissou MF, Chaffanet M, Plantaz D, Pasquier B, Schaerer R, Benabid A (1993) A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumours. Eur J Cancer 29A:753-759
20. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A 87:7160-7164
21. Nozaki M, Tada M, Matsumoto R, Sawamura Y, Abe H, Iggo RD (1998) Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay. Acta Neuropathol (Berl) 95:291-296
22. Pierre A, Leonce S, Perez V, Atassi G (1998) Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines. Cancer Chemother Pharmacol 42:454-460
23. Remsen LG, Trail PA, Hellstrom I, Hellstrom KE, Neuwelt EA (2000) Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 46:704-709
24. Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83:1029-1037
25. Solis-Recendez MG, Khayat D, Batist G (2000) Effect of taxol on apoptosis in a sensitive and resistant human small cell lung carcinoma (A549) (abstract). Proc Am Assoc Cancer Res 41:302
26. Takamiya Y, Abe Y, Tanaka Y, Tsugu A, Kazuno M, Oshika Y, Maruo K, Ohnishi Y, Sato O, Yamazaki H, Kijima H, Ueyama Y, Tamaoki N, Nakamura M (1997) Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xenografts. Br J Cancer 76:445-450
27. Trussardi A, Poitevin G, Gorisse MC, Faroux MJ, Bobichon H, Delvincourt C, Jardillier JC (1998) Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells. Int J Oncol 13:543-548
28. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) (1998) Guidelines for the Welfare of Animals in Experimental Neoplasia (second edition). Br J Cancer 77:1-10
29. Vassal G, Terrier-Lacombe MJ, Lellouch-Tubiana A, Valery CA, Sainte-Rose C, Morizet J, Ardouin P, Riou G, Kalifa C, Gouyette A (1996) Tumorigenicity of cerebellar primitive neuro-ectodermal tumors in athymic mice correlates with poor prognosis in children. Int J Cancer 69:146-151
30. Vassal G, Boland I, Santos A, Bissery MC, Terrier-Lacombe MJ, Morizet J, Sainte-Rose C, Lellouch-Tubiana A, Kalifa C, Gouyette A (1997) Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 73:156-163
31. Vassal G, Boland I, Terrier-Lacombe MJ, Watson AJ, Margison GP, Venuat AM, Morizet J, Parker F, Lacroix C, Lellouch-Tubiana A, Pierre-Kahn A, Poullain MG, Gouyette A (1998) Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Clin Cancer Res 4:463-468
32. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394:203-206
33. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3:523-530
34. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H (1999) Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 125:481-486
35. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Brunet J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593